Caligan Partners LP — 13F Holdings

2026 Q3  ·  31 Positions

2026 Q3 Portfolio Activity

In 2026 Q3, Caligan Partners LP maintained a portfolio of 31 distinct positions. The most significant new addition was OBSIDIAN THERAPEUTICS INC, now representing 0.74% of the total fund value. They heavily accumulated shares in REVOLUTION MEDICINES INC, increasing the position by 679.1%. Conversely, Caligan Partners LP completely exited their position in XENON PHARMACEUTICALS INC.
Position History hover any row below to update
Loading…
Caligan Partners LP New York, NY Hedge Fund AUM $1,634M
PCA Score Concentration Risk
Risk ENB
Total Positions
31
Quarter
2026 Q3
Top Holding
RVMD (24.6%)
Top 10 Concentration
78.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-31 of 31

Caligan Partners LP Full Holdings List — 2026 Q3

Stock History Sector / Type Port % Prev % Rank / Prev Conviction
Freshness
Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
RVMD
REVOLUTION MEDI...
Healthcare 24.64% 17.28% #1 1
Prev: #2
7.0
—
no change no change
P
S
1,961,795 $402,678,042 2025 Q1 13F Filing 2026-09-30 2026-11-16
LQDA
LIQUIDIA CORPOR...
Healthcare 15.03% 30.45% #2 1
Prev: #1
6.5
—
no change no change
P
S
8,118,892 $245,677,672 2022 Q4 13F Filing 2026-09-30 2026-11-16
ABVX
ABIVAX SA
Healthcare 9.44% 9.77% #3
Prev: #3
5.8
—
no change no change
P
S
1,557,924 $154,265,634 2024 Q4 13F Filing 2026-09-30 2026-11-16
PCVX
VAXCYTE INC
Healthcare 7.62% 5.99% #4
Prev: #4
4.5
—
no change no change
P
S
2,188,636 $124,533,388 2025 Q4 13F Filing 2026-09-30 2026-11-16
EXEL
EXELIXIS INC
Healthcare 5.55% 3.98% #5
Prev: #5
3.7
—
no change no change
P
S
1,553,262 $90,726,033 2023 Q1 13F Filing 2026-09-30 2026-11-16
TNGX
TANGO THERAPEUT...
Healthcare 3.82% 3.68% #6
Prev: #6
2.0
—
1,143 0.0%
P
S
2,501,246 $62,406,088 2025 Q4 13F Filing 2026-09-30 2026-11-16
ADMA
ADMA BIOLOGICS ...
Healthcare 3.61% 2.25% #7 2
Prev: #9
1.9
—
150,000 2.6%
P
S
5,875,007 $58,926,320 2022 Q4 13F Filing 2026-09-30 2026-11-16
IMCR
IMMUNOCORE HLDG...
Healthcare 3.10% 2.06% #8 4
Prev: #12
3.7
—
290,824 21.1%
P
S
1,672,141 $50,649,151 2026 Q2 13F Filing 2026-09-30 2026-11-16
AVTX
AVALO THERAPEUT...
Healthcare 3.07% 2.75% #9 2
Prev: #7
1.7
—
104,437 3.3%
P
S
3,268,303 $50,103,085 2025 Q3 13F Filing 2026-09-30 2026-11-16
LBRX
LB PHARMACEUTIC...
Healthcare 3.04% 2.20% #10 1
Prev: #11
1.7
—
71,551 5.0%
P
S
1,509,621 $49,621,242 2026 Q1 13F Filing 2026-09-30 2026-11-16
VRDN
VIRIDIAN THERAP...
Healthcare 2.76% 1.90% #11 2
Prev: #13
2.1
—
no change no change
P
S
2,193,981 $45,174,069 2026 Q2 13F Filing 2026-09-30 2026-11-16
VOR
VOR BIOPHARMA I...
Healthcare 2.25% 1.67% #12 2
Prev: #14
1.9
—
no change no change
P
S
1,925,066 $36,730,259 2025 Q4 13F Filing 2026-09-30 2026-11-16
IVA
INVENTIVA SA
Healthcare 2.07% 1.45% #13 3
Prev: #16
2.8
—
1,022,744 12.5%
P
S
9,185,935 $33,896,100 2025 Q4 13F Filing 2026-09-30 2026-11-16
IRD
OPUS GENETICS I...
Healthcare 1.77% 1.17% #14 5
Prev: #19
1.2
—
-116,112 -1.9%
P
S
5,960,972 $28,851,104 2026 Q1 13F Filing 2026-09-30 2026-11-16
AURA
AURA BIOSCIENCE...
Healthcare 1.76% 1.44% #15 2
Prev: #17
2.7
—
292,005 6.8%
P
S
4,590,253 $28,826,789 2025 Q2 13F Filing 2026-09-30 2026-11-16
ANIK
ANIKA THERAPEUT...
Healthcare 1.73% 0.99% #16 4
Prev: #20
1.7
—
no change no change
P
S
1,435,130 $28,214,656 2022 Q4 13F Filing 2026-09-30 2026-11-16
SABS
SAB BIOTHERAPEU...
Healthcare 1.69% 1.46% #17 2
Prev: #15
2.7
—
769,691 9.7%
P
S
8,736,898 $27,695,967 2026 Q1 13F Filing 2026-09-30 2026-11-16
SGMT
SAGIMET BIOSCIE...
Healthcare 1.69% 0.91% #18 3
Prev: #21
2.7
—
294,484 11.8%
P
S
2,794,484 $27,609,502 2026 Q2 13F Filing 2026-09-30 2026-11-16
SNSE
FAETH THERAPEUT...
Healthcare 1.62% 0.74% #19 4
Prev: #23
3.1
—
260,743 41.4%
P
S
890,210 $26,474,845 2026 Q1 13F Filing 2026-09-30 2026-11-16
TYRA
TYRA BIOSCIENCE...
Healthcare 1.22% 1.21% #20 2
Prev: #18
2.5
—
103,763 12.9%
P
S
910,749 $19,918,081 2025 Q1 13F Filing 2026-09-30 2026-11-16
OBX
OBSIDIAN THERAP...
Healthcare 0.74% — #21
Prev: #—
3.8
—
886,281 —
NEW
886,281 $12,168,638 2026 Q3 13F Filing 2026-09-30 2026-11-16
EPRX
EUPRAXIA PHARMA...
Healthcare 0.65% — #22
Prev: #—
3.8
—
1,163,010 —
NEW
1,163,010 $10,583,391 2026 Q3 13F Filing 2026-09-30 2026-11-16
ARTV
ARTIVA BIOTHERA...
Healthcare 0.65% 0.79% #23 1
Prev: #22
0.8
—
-255,068 -14.7%
P
S
1,481,043 $10,545,026 2026 Q2 13F Filing 2026-09-30 2026-11-16
VRCA
VERRICA PHARMAC...
Healthcare 0.27% 0.27% #24 1
Prev: #25
1.1
—
no change no change
P
S
923,910 $4,430,148 2023 Q3 13F Filing 2026-09-30 2026-11-16
N/A
TCGX ACQUISITIO...
Unknown 0.15% — #25
Prev: #—
3.6
—
200,000 —
NEW
200,000 $2,502,000 — 13F Filing 2026-09-30 2026-11-16
CLRB
CELLECTAR BIOSC...
Healthcare 0.05% 0.06% #26 2
Prev: #28
1.0
—
no change no change
P
S
469,998 $864,796 2026 Q2 13F Filing 2026-09-30 2026-11-16
ADMA
ADMA BIOLOGICS ...
CALL
CALL Option 0.00% 0.12%
Sold All 😨
(Was: #27)
0.0
—
-300,000 -100.0%
CLOSED
— $— 2022 Q4 13F Filing 2026-09-30 2026-11-16
AGIO
AGIOS PHARMACEU...
CALL
CALL Option 0.00% 0.16%
Sold All 😨
(Was: #26)
0.0
—
-90,000 -100.0%
CLOSED
— $— 2022 Q4 13F Filing 2026-09-30 2026-11-16
MBX
MBX BIOSCIENCES...
Healthcare 0.00% 0.52%
Sold All 😨
(Was: #24)
0.0
—
-200,000 -100.0%
CLOSED
— $— 2026 Q1 13F Filing 2026-09-30 2026-11-16
RVMD
REVOLUTION MEDI...
CALL
CALL Option 0.00% 2.22%
Sold All 😨
(Was: #10)
0.0
—
-251,800 -100.0%
CLOSED
— $— 2025 Q1 13F Filing 2026-09-30 2026-11-16
XENE
XENON PHARMACEU...
Healthcare 0.00% 2.53%
Sold All 😨
(Was: #8)
0.0
—
-889,944 -100.0%
CLOSED
— $— 2025 Q3 13F Filing 2026-09-30 2026-11-16
Showing 1-31 of 31 holdings

Unlock Full Caligan Partners LP Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →